Indication name: Interstitial cystitis (IC)
Interstitial cystitis (IC)/
bladder pain syndrome (BPS) – Market
outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019
To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy,
Japan & China)
Litrature suggested that females are 9
times more likely to be diagnosed with IC/PBS compared to males, and the risk
of IC/BPS increases with age. According to Thelansis prevalence ranges from
52-500/100,000 in females compared to 8-41/100,000 in males. The prevalence
increases to 1,431/100,000 for females with first-degree relatives IC/PBS which
suggests a hereditary component.
Competitive landscape of Interstitial
cystitis (IC) includes country specific approved as well as pipeline therapies.
Any asset/ product specific designation or review and Accelerated Approval are
being tracked and supplemented with analyst commentary.
Interstitial cystitis (IC) Market Forecasting: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs
with sourcing, Market Event and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden and pricing scenario, Summary and Insights.
KOLs insights of Interstitial cystitis
(IC) across 8 MM market from center of Excellence/ Public/ Private hospitals
participated in the study. Insights around current treatment landscape,
epidemiology, clinical characteristics, future treatment paradigm and Unmet
needs.
S. No Asset Company Stage
1
LiRIS® Allergan Phase 2
2
2% sodium chondroitin sulfate
Watson Pharmaceuticals Phase 2
4
LP-08 80mg Lipella
Pharmaceuticals, Inc. Phase 2
5
TTI-1612 Trillium
Therapeutics Inc. Phase 1
6
MN-001 MediciNova Phase 2
7
Device: Uracyst Stellar
Pharmaceuticals Phase 3
8
ASP6294 Astellas Pharma
Europe B.V. Phase 2
9
PD 0299685 Pfizer Phase 2
10 Adalimumab ICStudy, LLC Abbott Phase 3
11 SI-722 Seikagaku Corporation Phase 2
12 AQX-1125 Aquinox Pharmaceuticals (Canada) Inc.
Phase 3
13 Device: TC-3 Gel UroGen Pharma Ltd. Phase 2
14 URG101 Urigen Phase 2
15 Oxycodone naloxone DR Tabl Mundipharma
Research Phase 2
No comments:
Post a Comment